Financial Review Article: 4DMedical float set to sizzle, as funds pile in
“In the eight years since former Monash University professor Andreas Fouras founded soon-to-be listed lung imaging medical technology company 4D Medical, he has put everything on the line to get his business to where it is today.
When the company floats on the ASX on Friday with a market capitalisation of $193 million and an issue price of 73¢ per share, it will vindicate the decision by Dr Fouras and his family to sell their house, put all their savings into the business, give up their lives in Australia and move to the US…”
To read the full article on Financial Review, click here.
Andreas Fouras first conceptualized a novel four-dimensional X-ray imaging technology to study the function of the breathing lungs in 2005. He developed the subsequent technology of the 4DxV platform in the years following with his research group, the Laboratory for Dynamic Imaging at Monash University, Melbourne, Australia.
Having raised over AU$10 million in research funding from agencies including Australia’s National Health & Medical Research Council (NHMRC), the Australian Research Council, and the American Asthma Foundation, Andreas, his collaborators and his research team successfully translated the technology into the laboratory where it could be developed for clinical use.
4Dx was incorporated in December 2012 to commercialise the technology and commenced operations in July 2013 with key researchers involved in the technology’s research development now engaged with its commercial development.
The technology has been extensively patented, with core patents granted in key jurisdictions including the United States and Australia. The technology has been proven through published preclinical studies over the past 15 years. 4Dx obtained FDA clearance for its first product, XV Lung Ventilation Analysis Software (XV LVAS), in May 2020 and rebranded to 4DMedical in preparation for its listing on the ASX.